SI3299377T1 - Modulacija strukturirane specifičnosti polipeptida - Google Patents
Modulacija strukturirane specifičnosti polipeptidaInfo
- Publication number
- SI3299377T1 SI3299377T1 SI201231892T SI201231892T SI3299377T1 SI 3299377 T1 SI3299377 T1 SI 3299377T1 SI 201231892 T SI201231892 T SI 201231892T SI 201231892 T SI201231892 T SI 201231892T SI 3299377 T1 SI3299377 T1 SI 3299377T1
- Authority
- SI
- Slovenia
- Prior art keywords
- modulation
- polypeptide specificity
- structured polypeptide
- structured
- specificity
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1117408.3A GB201117408D0 (en) | 2011-10-07 | 2011-10-07 | Modulation of structure polypeptide specificity |
| GBGB1205612.3A GB201205612D0 (en) | 2012-03-29 | 2012-03-29 | Modulation of structured polypeptide specificity |
| EP17188298.8A EP3299377B1 (en) | 2011-10-07 | 2012-10-08 | Modulation of structured polypeptide specificity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3299377T1 true SI3299377T1 (sl) | 2021-07-30 |
Family
ID=47080465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231892T SI3299377T1 (sl) | 2011-10-07 | 2012-10-08 | Modulacija strukturirane specifičnosti polipeptida |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9994617B2 (sl) |
| EP (2) | EP2764140B1 (sl) |
| JP (3) | JP6254527B2 (sl) |
| CN (1) | CN103906865B (sl) |
| AU (1) | AU2012320407B2 (sl) |
| BR (1) | BR112014008156A2 (sl) |
| CA (1) | CA2849948C (sl) |
| CY (1) | CY1123865T1 (sl) |
| DK (1) | DK2764140T3 (sl) |
| ES (1) | ES2650625T3 (sl) |
| HK (1) | HK1252864A1 (sl) |
| HR (1) | HRP20210394T1 (sl) |
| HU (1) | HUE053389T2 (sl) |
| LT (1) | LT3299377T (sl) |
| NO (1) | NO2764140T3 (sl) |
| PL (1) | PL2764140T3 (sl) |
| PT (1) | PT2764140T (sl) |
| RU (2) | RU2631931C2 (sl) |
| SG (1) | SG11201400888TA (sl) |
| SI (1) | SI3299377T1 (sl) |
| WO (2) | WO2013050615A1 (sl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9994617B2 (en) * | 2011-10-07 | 2018-06-12 | Bicyclerd Limited | Modulation of structured polypeptide specificity |
| EP2850095B1 (en) | 2012-05-17 | 2019-10-09 | RA Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| ES2715379T3 (es) * | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
| DK3215518T3 (da) * | 2014-10-29 | 2021-05-25 | Bicyclerd Ltd | Bicykliske peptidligander, der er specifikke for mt1-mmp |
| WO2017124066A1 (en) * | 2016-01-14 | 2017-07-20 | Arrowhead Pharmaceuticals, Inc. | Method of modifying a peptide |
| GB201607827D0 (en) * | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| CN110603261A (zh) * | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| MX2019007367A (es) * | 2016-12-23 | 2020-01-27 | Bicycletx Ltd | Ligandos de peptido para enlace a mt1-mmp. |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| WO2018144849A1 (en) * | 2017-02-02 | 2018-08-09 | The University Of Akron | Functionalized poly(propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts |
| EP3585420A4 (en) | 2017-02-22 | 2021-04-07 | Bioincept LLC | PEPTIDES AND METHODS OF TREATMENT OF DYSTROPHY RELATED CONDITIONS USING THEM |
| CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
| US20200246424A1 (en) | 2017-07-17 | 2020-08-06 | Bioincept, Llc | Peptides and methods of transplantation and restorative organ function |
| CN118772242A (zh) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| WO2019034866A1 (en) * | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CN108191955B (zh) * | 2018-01-11 | 2020-05-19 | 中国科学院化学研究所 | 一种肽两亲分子及其制备方法与应用 |
| EP3774851A1 (en) * | 2018-04-04 | 2021-02-17 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| GB201808835D0 (en) * | 2018-05-30 | 2018-07-11 | Bicyclerd Ltd | Ligands and methods of selecting binding targets for such |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| CA3112545A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| CA3111784A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Methods and compositions for the treatment of disease with immune stimulatory conjugates |
| JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
| CN109627301B (zh) * | 2019-02-18 | 2022-08-05 | 浙江新银象生物工程有限公司 | Nisin固体稳定剂开发及应用 |
| US20220267379A1 (en) * | 2019-07-15 | 2022-08-25 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel inhibitors of kallikrein proteases and uses thereof |
| TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| JP2022544543A (ja) | 2019-08-15 | 2022-10-19 | シルバーバック セラピューティックス インコーポレイテッド | ベンザゼピンコンジュゲートの製剤およびその使用 |
| WO2021064428A1 (en) | 2019-10-03 | 2021-04-08 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145233C1 (ru) * | 1990-07-02 | 2000-02-10 | Дзе Аризона Борд оф Риджентс | Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом |
| DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| US20030166003A1 (en) | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| WO2005122379A2 (en) | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| ES2428869T3 (es) | 2005-01-24 | 2013-11-12 | Pepscan Systems B.V. | Compuestos de unión, compuestos inmunógenos y peptidomiméticos |
| EP2374472B9 (en) | 2006-03-16 | 2019-06-12 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
| JP2009544697A (ja) * | 2006-07-26 | 2009-12-17 | ペプスキャン システムズ ベー．フェー． | 免疫原性化合物及びタンパク質擬態物 |
| PL2257624T3 (pl) | 2008-02-05 | 2012-09-28 | Medical Res Council | Sposoby i kompozycje |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| WO2013022342A1 (en) | 2011-08-09 | 2013-02-14 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | A method of analysing a blood sample of a subject for the presence of a foetal disease or condition marker |
| US9994617B2 (en) | 2011-10-07 | 2018-06-12 | Bicyclerd Limited | Modulation of structured polypeptide specificity |
| GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) * | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| ES2715379T3 (es) | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
-
2012
- 2012-10-08 US US14/350,263 patent/US9994617B2/en active Active
- 2012-10-08 BR BR112014008156A patent/BR112014008156A2/pt not_active Application Discontinuation
- 2012-10-08 WO PCT/EP2012/069897 patent/WO2013050615A1/en active Application Filing
- 2012-10-08 NO NO12778672A patent/NO2764140T3/no unknown
- 2012-10-08 PT PT127786721T patent/PT2764140T/pt unknown
- 2012-10-08 WO PCT/EP2012/069898 patent/WO2013050616A1/en active Application Filing
- 2012-10-08 LT LTEP17188298.8T patent/LT3299377T/lt unknown
- 2012-10-08 EP EP12778672.1A patent/EP2764140B1/en active Active
- 2012-10-08 HU HUE17188298A patent/HUE053389T2/hu unknown
- 2012-10-08 RU RU2014118461A patent/RU2631931C2/ru active
- 2012-10-08 JP JP2014533945A patent/JP6254527B2/ja active Active
- 2012-10-08 AU AU2012320407A patent/AU2012320407B2/en active Active
- 2012-10-08 RU RU2017132824A patent/RU2745572C2/ru active
- 2012-10-08 US US14/350,192 patent/US10800813B2/en active Active
- 2012-10-08 PL PL12778672T patent/PL2764140T3/pl unknown
- 2012-10-08 CA CA2849948A patent/CA2849948C/en active Active
- 2012-10-08 CN CN201280049406.8A patent/CN103906865B/zh active Active
- 2012-10-08 ES ES12778672.1T patent/ES2650625T3/es active Active
- 2012-10-08 DK DK12778672.1T patent/DK2764140T3/en active
- 2012-10-08 SI SI201231892T patent/SI3299377T1/sl unknown
- 2012-10-08 EP EP17188298.8A patent/EP3299377B1/en active Active
- 2012-10-08 SG SG11201400888TA patent/SG11201400888TA/en unknown
-
2017
- 2017-07-31 JP JP2017147687A patent/JP6568161B2/ja active Active
-
2018
- 2018-09-21 HK HK18112198.5A patent/HK1252864A1/zh unknown
-
2019
- 2019-08-01 JP JP2019142001A patent/JP6906571B2/ja active Active
-
2020
- 2020-06-11 US US16/899,192 patent/US11912794B2/en active Active
-
2021
- 2021-02-26 CY CY20211100165T patent/CY1123865T1/el unknown
- 2021-03-08 HR HRP20210394TT patent/HRP20210394T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252864A1 (zh) | 結構化多肽特異性的調控 | |
| HUS1900001I1 (hu) | Transztiretin expressziójának módosítása | |
| HRP20181440T1 (hr) | Retinoidni liposomi, namijenjeni poboljšavanju moduliranja eksprimiranja hsp47 | |
| HK1221172A1 (zh) | 結構化多肽特異性的調控 | |
| HK1201555A1 (en) | Antisense modulation of gccr expression gccr | |
| EP2595664A4 (en) | MODULATION OF NUCLEAR RETENTION RNA | |
| HK1207078A1 (en) | Inhibition of enzymes | |
| ZA201403108B (en) | Purification of anti-c-met antibodies | |
| IL227656A0 (en) | Immunoglobulin site engineering | |
| PL3461895T3 (pl) | Modulacja ekspresji ube3a-ats | |
| EP2776564A4 (en) | MODULATION OF TMPRSS6.EXPRESSION | |
| PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
| IL228773B (en) | Antisense modulation of b1ptp expression | |
| EP3560952C0 (en) | VARIANT OF BPIFB4 PROTEIN | |
| EP2625280A4 (en) | MODULATION OF VSEL-TYPE STEM CELLS BY IGF-1 | |
| GB201117408D0 (en) | Modulation of structure polypeptide specificity | |
| GB201205612D0 (en) | Modulation of structured polypeptide specificity | |
| HK1201420A1 (en) | Use of amylase enzyme |